|Year : 2015 | Volume
| Issue : 9 | Page : 751-752
Smt. Kanuri Santhamma Retina Vitreous Centre, L. V. Prasad Eye Institute, Hyderabad, Telangana, India
|Date of Web Publication||3-Dec-2015|
Dr. Jay Chhablani
Smt. Kanuri Santhamma Retina Vitreous Centre, L.V. Prasad Eye Institute, Kallam Anji Reddy Campus, L. V. Prasad Marg, Banjara Hills, Hyderabad - 500 034, Telangana
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Chhablani J. Author reply. Indian J Ophthalmol 2015;63:751-2
I appreciate comments from the authors. I am glad that article on ziv-aflibercept has attracted attention from readers for Indian Journal of Ophthalmology. I agree with the authors that we do not have long-term data on ziv-aflibercept; therefore, I reported short-term safety results. After observing no clinical side effects in injected eye on the 5th day, I injected in the other eye. The patient was stable during the treatment-free interval with visual acuity of 20/100 before the recurrent attack. The response to ziv-aflibercept was better than bevacizumab. Therefore, ziv-aflibercept was considered as the treatment of choice at 1-month follow-up as well. The patient is under regular treatment until now. Therefore, I am unable to comment upon whether ziv-aflibercept prolonged the treatment-free interval or not.
Again, I appreciate authors’ interest in this article.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Sen A, Mitra A, Malhotra PP, Gupta S. Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion. Indian J Ophthalmol 2015;63:752.